Recombinant Human SLP-76 (N-T7,C-6His)

Description

EnkiLife provides the Recombinant Human SLP-76 (N-T7,C-6His) protein,aslo know as Lymphocyte cytosolic protein 2,SH2 domain-containing leukocyte protein of 76 kDa,SLP-76 tyrosine phosphoprotein,SLP76,LCP2, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Lymphocyte Cytosolic Protein 2/SH2 Domain-containing Leukocyte Protein of 76 kDa is produced by our E.coli expression system and the target gene encoding Met1-Pro533 is expressed with a T7 tag at the N-terminus, 6His tag at the C-terminus.Accession:Q13094. Expression Host:E.coli.Species:Human.Predicted Molecular Mass:62.6 KDa. Background:Lymphocyte cytosolic protein 2（LCP2）contains a SAM domain and a SH2 domain. It is highly expressed in spleen, thymus and peripheral blood leukocytes, T-cell and monocytic cell lines, but expressed at lower level in B-cell lines. LCP2 was originally identified as a substrate of the ZAP-70 protein tyrosine kinase following T cell receptor (TCR) ligation in the leukemic T cell line Jurkat. It is phosphorylated after T-cell receptor activation by ZAP70, ITK and TXK, which leads to the up-regulation of Th1 preferred cytokine IL-2 during post-translational modification. Studies using LCP2-deficient T cell lines or mice have provided strong evidence that SLP-76 plays a positive role in promoting T cell development and activation as well as mast cell and platelet function.